New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 22, 2013
12:14 EDTIP, MOS, ADM, NVS, SCCOStocks with increasing implied volatility: NVS MOS SCCO ADM IP
News For NVS;MOS;SCCO;ADM;IP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
October 1, 2015
07:37 EDTNVSXOMA announces agreement for anti-TGFb program with Novartis
Subscribe for More Information
06:12 EDTMOSMosaic to pay $1.8B settlement to clean fertilizer waste, AP reports
Subscribe for More Information
06:09 EDTMOSMosaic Fertilizer reaches regulatory settlement in Florida, Louisiana
Subscribe for More Information
September 30, 2015
17:04 EDTNVSNovartis says results of Phase 3 study of secukinumab met endpoints
Subscribe for More Information
September 29, 2015
12:35 EDTNVSPerrigo shareholders pressure company to explore sale, Reuters says
Certain Perrigo (PRGO) shareholders have requested that company explore a sale, hoping for an alternative to Mylan's (MYL) approximately $25B hostile bid, Reuters reports, citing people familiar with the matter. The pressure represents a challenge to Perrigo's defense strategy, the report says. Some of the company's shareholders view Novartis (NVS), Sanofi (SNY), Procter & Gamble (PG), and Colgate-Palmolive (CL) as potential suitors, the report says. Reference Link
10:00 EDTSCCOOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARM Holdings (ARMH) downgraded to Neutral from Buy at Natixis... Arthur J. Gallagher (AJG) downgraded to Hold from Buy at Sandler ONeill... CareDx (CDNA) downgraded to Market Perform from Outperform at Raymond James... Carlisle (CSL) downgraded to Sector Weight from Overweight at KeyBanc... Imation (IMN) downgraded to Hold from Buy at Lake Street... Mediaset Espana (GETVF) downgraded to Underweight from Equal Weight at Barclays... New Source Energy (NSLP) downgraded to Sell from Hold at Wunderlich... Peugeot (PUGOY) downgraded to Buy from Conviction Buy at Goldman... RTL Group (RGXLY) downgraded to Equal Weight from Overweight at Barclays... Regal-Beloit (RBC) downgraded to Neutral from Buy at Buckingham... Sequenom (SQNM) downgraded to Market Perform from Outperform at William Blair... Southern Copper (SCCO) downgraded to Sector Perform at Scotia Howard Weil... TerraForm Global (GLBL) downgraded to Neutral from Overweight at JPMorgan... Verastem (VSTM) downgraded to Hold from Buy at Jefferies... Vital Therapies (VTL) downgraded to Neutral from Buy at SunTrust... Williams (WMB) downgraded to Sector Perform from Outperform at Scotia Howard Weil.
08:46 EDTNVSNoven reports final decisions in IPRs challenging Novartis' Exelon patch patents
Subscribe for More Information
08:25 EDTSCCOSouthern Copper downgraded to Sector Perform at Scotia Howard Weil
Subscribe for More Information
07:03 EDTSCCOSouthern Copper volatility at upper end of 52-week range
Southern Copper 30-day option implied volatility is at 46; compared to its 52-week range of 23 to 54, suggesting large price movement.
September 28, 2015
12:22 EDTNVSArray says binimetinib-encorafenib combo shows differentiated tolerability
Subscribe for More Information
07:58 EDTNVSNovartis to hold a conference call
Subscribe for More Information
September 27, 2015
18:48 EDTNVSNovartis reports updated Phase 3 data on Tafinlar-Mekinist for melanoma
Subscribe for More Information
16:16 EDTNVSNovartis reports Phase 3 reults on Afinitor for neuroendocrine tumors
Novartis announced results of a Phase 3 pivotal study showing Afinitor, or everolimus, tablets reduced the risk of progression by 52% versus placebo in patients with advanced, progressive, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin. Additionally, the data show everolimus, a mammalian target of rapamycin inhibitor, extended median progression free survival by 7.1 months. Median PFS by central review was 11 months in the everolimus arm and 3.9 months in the placebo arm. Overall survival was a key secondary endpoint of the trial. While the OS data are not mature, the first interim analysis showed a trend favoring the everolimus arm, according to Novartis. Additional analyses are planned. Another secondary endpoint was best overall response rate. The study found that 64% of patients receiving everolimus experienced at least some degree of tumor shrinkage compared to 26% of those on placebo. Adverse events were consistent with the known safety profile of everolimus. The results of the RADIANT-4 study will serve as the basis of worldwide regulatory submissions for Afinitor for the treatment of advanced, progressive, nonfunctional GI and lung NET, Novartis said.
September 25, 2015
07:55 EDTIPContainerboard stocks oversold at current levels, says Jefferies
Jefferies analyst Philip Ng believes containerboard stocks are already pricing in a $30-60/ton price decline. Industry contracts, however, expect downtime will balance the market and prices will hold, Ng tells investors in a research note. International Paper (IP), WestRock (WRK) and Packaging Corp. (PKG) are oversold at current levels and should be attractive for long term investors, Ng writes. He has a Buy rating on all three names.
07:22 EDTNVSEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
05:15 EDTNVSNovartis announces CHMP adopted positive opinion for Entresto
Subscribe for More Information
September 24, 2015
18:38 EDTNVSNovartis CEO discusses drug pricing, paying doctors, Washington Post reports
Novartis CEO Joseph Jimenez said in an interview with the Washington Post, "Drug pricing is a very complicated topic because we invest in high-risk activity... So when we price a drug, we price it based on the value it will bring into that marketplace, and also how its price compares to the other therapies currently on the market. There's been a lot of discussion about drug pricing. What we have to do is we have to shift that conversation away from the price toward the value. Like, what exactly is the value of this drug that is going to result in a positive outcome? And is society willing to pay for that drug? At Novartis, we take a little bit of a different approach than our peers. Not only are we a large, innovative drug manufacturer, but we also are the second largest generics manufacturer... I also believe at Novartis that the day that patents expire, it's our obligation to offer a low-cost version in a generic form." Discussing the practice of drug companies paying doctors to prescribe particular drugs, Jiminez said, "It's unfortunate, because that's a situation where society's expectations have changed to the point where even doing what's legal is not doing what's right. What we have to do is, we have to find new ways to educate physicians about our new drugs... We're looking at ways digitally to communicate with physicians and at some new tools, so we can stay ahead of the curve. So rather than wait for regulations to change, Novartis can step back and say, 'We're going to do what society would expect us to do, not just do what's legal.'" Reference Link
09:07 EDTNVSUnilife ammends clinical supply agreement with Novartis
Subscribe for More Information
September 23, 2015
15:44 EDTMOS52-week low stocks with active options: WYNN SNCR PX MON MOS DECK
Subscribe for More Information
07:47 EDTMOSJPMorgan cuts targets for Mosaic and Potash but still sees value
JPMorgan analyst Jeffrey Zekauskas says weakening demand and price trends for potash does not bode well for the China and India contracts for 2016. The analyst reduced his earnings expectations for Potash (POT) and Mosaic (MOS), but keeps Overweight ratings on both citing their "value characteristics." He cut his price target for Potash to $26 from $34 and for Mosaic to $40 from $52.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use